News Feed Item

Seven Bridges becomes a Google Cloud Technology Partner to support life science researchers

CAMBRIDGE, Mass., May 15, 2018 /PRNewswire/ -- Seven Bridges Genomics Inc., a leading biomedical data platform and analytics company, today announced it has become a certified Google Cloud Technology Partner.  The Seven Bridges Platform deployment on Google Cloud offers researchers confronted with the myriad challenges of big data bioinformatics an end-to-end solution to accelerate data processing and scientific discovery.  The collaboration brings together the data management and analysis flexibility of the Seven Bridges Platform with the class-leading infrastructure of Google Cloud Platform.

"Deepening our relationship with Google Cloud by joining the Technology Partner Program allows us to work closely to develop unique capabilities," said Brandi Davis-Dusenbery, Ph.D., Chief Executive Officer at Seven Bridges.  "Not only are we broadening the scope of what we can offer our users, but we're excited to be working with Google Cloud's Healthcare and Life Sciences Solutions group on developing the tools and data assets that will benefit the broader community."

Seven Bridges specializes in software and data analytics that help researchers turn raw genomic and clinical data into actionable results. The Seven Bridges ecosystem includes the commercial Seven Bridges Platform and collaborative platforms based on Seven Bridges' core technology, such as the Cancer Genomics Cloud.  Seven Bridges supports thousands of researchers in biopharma, government, and academia, as well as some of the world's largest national genomics research programs, including the National Institutes of Health Data Commons Pilot Phase Consortium, Genomics England's 100,000 Genome Project and the Million Veteran Program

[email protected]

Cision View original content with multimedia:

SOURCE Seven Bridges Genomics Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.